retatrutide benefits besides weight loss with as compared to currently licenced obesity Retatrutide and the Grey Market:

The effect of using GLP-1RAs on respiratory disease is unknown

October 2025 : The Wegovy warning label was updated to include Severe Gastrointestinal Adverse Reactions in the WARNINGS AND PRECAUTIONS section

Insurance coverage for GLP-1 medications like Ozempic has become increasingly restrictive, with most major carriers including Aetna limiting approval to patients with diagnosed type 2 diabetes rather than obesity alone

Eur J Heart Fail 22:14951503 Seferovi PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, avuolu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferovi J, Jhund PS, Dattilo G, elutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainak M, Jankowska E, Mueller C, Cosentino F, Lund LH, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC (2020) Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure